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Assessment of HMGA2 and PLAG1 rearrangements in breast
adenomyoepitheliomas
Fresia Pareja1, Felipe C. Geyer1, David N. Brown1, Ana P. Martins Sebastião1, Rodrigo Gularte-Mérida1, Anqi Li1, Marcia Edelweiss1,
Arnaud Da Cruz Paula1, Pier Selenica1, Hannah Y. Wen1, Achim A. Jungbluth1, Zsuzsanna Varga2, Juan Palazzo3, Brian P. Rubin4, Ian O.
Ellis5, Edi Brogi1, Emad A. Rakha5, Britta Weigelt1 and Jorge S. Reis-Filho1
Breast adenomyoepitheliomas (AMEs) are rare epithelial-myoepithelial neoplasms that may occasionally produce myxochondroid
matrix, akin to pleomorphic adenomas (PAs). Regardless of their anatomic location, PAs often harbor rearrangements involving
HMGA2 or PLAG1. We have recently shown that the repertoire of somatic genetic alterations of AMEs varies according to their
estrogen receptor (ER) status; whilst the majority of ER-positive AMEs display mutually exclusive PIK3CA or AKT1 hotspot mutations,
up to 60% of ER-negative AMEs harbor concurrent HRAS Q61 hotspot mutations and mutations affecting either PIK3CA or PIK3R1.
Here, we hypothesized that a subset of AMEs lacking these somatic genetic alterations could be underpinned by oncogenic fusion
genes, in particular those involving HMGA2 or PLAG1. Therefore, we subjected 13 AMEs to RNA-sequencing for fusion discovery
(n= 5) and/or ﬂuorescence in situ hybridization (FISH) analysis for HMGA2 and PLAG1 rearrangements (n= 13). RNA-sequencing
revealed an HMGA2-WIF1 fusion gene in an ER-positive AME lacking HRAS, PIK3CA and AKT1 somatic mutations. This fusion gene,
which has been previously described in salivary gland PAs, results in a chimeric transcript composed of exons 1–5 of HMGA2 and
exons 3–10 ofWIF1. No additional in-frame fusion genes or HMGA2 or PLAG1 rearrangements were identiﬁed in the remaining AMEs
analyzed. Our results demonstrate that a subset of AMEs lacking mutations affecting HRAS and PI3K pathway-related genes may
harbor HMGA2-WIF1 fusion genes, suggesting that a subset of breast AMEs may be genetically related to PAs or that a subset of
AMEs may originate in the context of a PA.
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INTRODUCTION
Breast adenomyoepitheliomas (AMEs) are rare neoplasms with
dual epithelial-myoepithelial differentiation,1 composed of gland-
like structures containing an inner layer of pink, eosinophilic
epithelial cells and an abluminal layer of often clear, myoepithelial
cells. AMEs can display a variety of histologic appearances, and be
either estrogen receptor (ER)-positive or ER-negative.1,2 Although
there is overlap in the histologic features of ER-positive and ER-
negative AMEs, we have recently shown that the repertoire of
genetic alterations of these tumors vary according to their ER
status.3 Whilst ER-negative AMEs harbor HRAS Q61 hotspot
mutations co-occurring with mutations affecting PIK3CA or PIK3R1
in up to 60% of cases, the majority of ER-positive AMEs were
found to display seemingly mutually exclusive PIK3CA or AKT1
activating hotspot mutations.3
In the spectrum of histologic appearances of AMEs, myxochon-
droid matrix has been occasionally described.4 This type of matrix
bears histologic resemblance to the matrix of pleomorphic
adenomas (PAs),1 epithelial-myoepithelial neoplasms that may
arise in various anatomic locations, including the breast.5 PAs are
underpinned by recurrent gene rearrangements involving HMGA2
or PLAG1 in up to 65% of cases, regardless of their anatomic
origin.6–8 Due to the overlapping histologic appearances of AMEs
and PAs, we sought to determine whether a subset of AMEs,
primarily those lacking mutations affecting known drivers (e.g.,
HRAS or PI3K pathway-related genes), would be genetically related
to PAs, and would be underpinned by fusion genes, in particular
those involving HMGA2 and PLAG1.
RESULTS
HMGA2-WIF1 fusion gene in an ER-positive AME
Thirteen breast AMEs, whose whole-exome, targeted capture and/
or Sanger sequencing and ER status were previously described in
Geyer et al,3 were included in this study (Table 1). Six cases were
ER-negative and seven were ER-positive. Four ER-negative AMEs
harbored concurrent PIK3CA and HRAS mutations (4/6), one
harbored an HRAS Q61K mutation and concurrent likely patho-
genic PIK3R1 mutations (1/6), and one was HRAS wild-type and
harbored a PIK3CA mutation (1/6). Five ER-positive AMEs harbored
PIK3CA mutations (5/7), and all were wild-type for HRAS. None of
the cases harbored mutations affecting the AKT1 E17 hotspot
locus (Fig. 1a and Supplementary Fig. 1). Notably, all HRAS and
PIK3CA mutations were classical activating hotspot mutations,
except for one PIK3CA mutation (Q546) which targeted a hotspot
residue and was predicted to be likely pathogenic (Fig. 1a).
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To determine whether AMEs lacking HRAS Q61 hotspot
mutations would harbor fusion genes, we subjected ﬁve HRAS
wild-type AMEs with available material to RNA-sequencing
analysis for an unbiased detection of expressed fusion genes
(Supplementary Fig. 1). Using a validated pipeline for the de novo
discovery of fusion genes,9 we identiﬁed an HMGA2-WIF1 fusion
gene in an ER-positive HRAS-/PIK3CA-/AKT1-wild-type AME (AM16)
(Figs. 1a-c, Table 1 and Supplementary Table 1). The HMGA2-WIF1
fusion gene identiﬁed in AM16 results in a chimeric transcript
encompassing all ﬁve exons and the initial segment of the 3′ UTR
of HMGA2 fused to exons 3–10 of WIF1, and is predicted to be
translated to a full length HMGA2 protein and an N-terminal
truncated WIF1 protein, with a truncated WIF domain. WIF1
encodes for a tumor suppressor that modulates Wnt signaling, a
role that requires an intact WIF domain.10
The AME found to harbor the HMGA2-WIF1 fusion gene (AM16)
displayed the typical histologic features of AMEs,3 and constituted
a well-circumscribed lesion with pushing borders, surrounded by a
thick ﬁbrous capsule. This lesion displayed a nodular architecture
and a mixed tubular and papillary growth pattern. No cellular
atypia, mitotic activity or necrosis was identiﬁed (Fig. 1c). Focal
areas with conspicuous stroma with myxoid quality were observed
(Fig. 1c). The myoepithelial component was highlighted by p63 on
immunohistochemical analysis, and strong ER expression was
observed in the epithelial component (Fig. 1c).
Given that in the salivary glands, epithelial-myoepithelial
carcinomas, the salivary gland counterpart of breast AME, can
occasionally originate in the context of a PA (i.e., the so-called
carcinoma ex-PA),11 we sought to deﬁne if AM16 would have
areas diagnostic of PA. An independent pathology review of all
slides available from this AME by ﬁve pathologists failed to reveal
any areas that would be consistent with a diagnosis of PA.
Breast AMEs lack recurrent HMGA2 or PLAG1 rearrangements
None of the additional AMEs subjected to RNA-sequencing
harbored other fusion genes involving gene partners previously
described in PAs,12 in myoepitheliomas of other anatomical sites
(i.e., EWSR1 and FUS rearrangements),13,14 or in other tumors
displaying myoepithelial differentiation (i.e., CRTC1-MAML2 fusion
gene in mucoepidermoid carcinomas or MYB and MYBL1
rearrangements in adenoid cystic carcinoma).9,15 No additional
likely pathogenic in-frame fusion gene was identiﬁed in the cases
subjected to RNA-sequencing analysis (Supplementary Table 1).
Given that HMGA2 and PLAG1 rearrangements have been
described in other neoplasms with epithelial-myoepithelial
differentiation, in particular in PAs, we sought to deﬁne whether
AMEs may harbor fusion genes known to underpin PAs. We
subjected the ﬁve AMEs analyzed by RNA-sequencing and all the
other AMEs included in this study (n= 8) to FISH using HMGA2
and PLAG1 dual-color break apart probes (Table 1 and Supple-
mentary Fig. 1). This analysis conﬁrmed the presence of an HMGA2
rearrangement in both the epithelial and myoepithelial compo-
nents of AM16 (Fig. 2b) and did not reveal any additional AMEs
harboring HMGA2 or PLAG1 rearrangements (Table 1).
DISCUSSION
We have previously shown that approximately 60% ER-positive
AMEs harbor PIK3CA or AKT1 mutations, whereas up to 60% of ER-
negative AMEs are characterized by HRAS Q61 mutations
concurrent with mutations affecting genes of the PI3K signaling
pathway.3 Given the occasional histologic similarities between
AMEs and PAs, and the fact that a subset of AMEs lack a known
driver genetic alteration in the form of somatic mutations
affecting protein coding genes, we posited that a subset of AMEs
may harbor oncogenic fusion genes previously described in other
myoepithelial lesions including PAs. Our analyses resulted in the
identiﬁcation of an ER-positive HRAS-/PIK3CA-/AKT1-wild type AME
harboring an HMGA2-WIF1 fusion gene, which has been described
in PAs and carcinomas ex-PA of the salivary gland.10,16
The high-mobility group AT-hook 2 (HMGA2) gene encodes for a
transcriptional regulator of genes involved in cell proliferation and
cell death.17 HMGA2 overexpression plays a key role in oncogenic
transformation through several mechanisms, such as the induc-
tion of E2F1 and AP1 activity, promotion of cyclin A expression,
inactivation of p53-dependent apoptosis, and activation of the
TGF-β signaling pathway.17,18 The Wnt signaling pathway is
regulated by secreted antagonists that bind to Wnt proteins,
preventing ligand-receptor interactions,19 such as WIF1.20 WIF1
consists of an N-terminal secretion signal, ﬁve EGF-like domains, a
hydrophilic C-terminus, and a WIF domain, which is required for
binding to Wnt proteins and for the tumor suppressor properties
of WIF1.19 The HMGA2-WIF1 fusion gene identiﬁed in AM16 has
been shown to result in increased HMGA2 expression, presumably
Table 1. Clinicopathological and selected genetic features of the 13 breast adenomyoepitheliomas included in this study
Case ID ER status PIK3CA status AKT1
status
PIK3R1 status HRAS
status
Oncogenic fusion genes by RNA
sequencing
PLAG1/ HMGA2 rearrangement by
FISH
AM1 Negative MUT WT WT MUT NT Negative
AM4 Negative MUT WT WT MUT NT Negative
AM8 Negative MUT WT WT MUT NT Negative
AM11 Negative MUT WT NT MUT NT Negative
AM5 Negative WT WT MUT MUT NT Negative
AM7 Negative MUT WT WT WT None Negative
AM2 Positive MUT WT WT WT None Negative
AM3 Positive MUT WT WT WT None Negative
AM12 Positive MUT WT NT WT NT Negative
AM13 Positive MUT WT NT WT NT Negative
AM17 Positive MUT WT NT WT NT Negative
AM16 Positive WT WT NT WT HMGA2-WIF1 Positive (HMGA2)
AM6 Positive WT WT WT WT None Negative
ER estrogen receptor, MUT mutant, NT not tested, WT wild-type
F. Pareja et al.
2
npj Breast Cancer (2019)     6 Published in partnership with the Breast Cancer Research Foundation
1
2
3
4
5
6
7
8
9
0
()
:,;
due to loss of regulatory sites in its 3′ UTR,21 and decreased WIF1
expression.10 The HMGA2-WIF1 chimeric transcript identiﬁed in our
study is predicted to encode a full length HMGA2 protein and an
N-terminally truncated WIF1 protein harboring a truncated WIF
domain. Given that the HMGA2 breakpoint maps to its 3’ UTR after
the stop codon, it is possible that WIF1 may not even be
translated, akin to a rearrangement involving the same HMGA2
and WIF1 exons previously described in a PA arising in the salivary
gland.16 In addition, HMGA2 and WIF1 display opposite transcrip-
tional orientations, and this fusion gene may stem from a cryptic
paracentric inversion (Fig. 2a).16
Taken together, the HMGA2-WIF1 fusion identiﬁed here might
result in increased expression of HMGA2, with ensuing activation
of TGF-β signaling, along with derepression of Wnt signaling.
Taken together, our ﬁndings suggest that a subset of AMEs lacking
genetic alterations involving genes of the RAS-MAPK pathway
may be underpinned by fusion genes resulting in the activation of
alternative signaling pathways, such as TGF-β and Wnt.
One could posit that the AME harboring the HMGA2-WIF1 fusion
gene described in this study would, in fact, constitute a breast PA.
This case was independently reviewed by ﬁve breast pathologists
who concurred in the diagnosis of AME. It should be noted,
however, that despite being a bona ﬁde AME, this case focally
displayed increased myxoid stroma, bearing some resemblance to,
but not fulﬁlling the diagnostic criteria for, a breast PA. Another
potential explanation for the presence of this fusion gene in AM16
is that it would constitute the breast equivalent of the salivary
gland epithelial-myoepithelial carcinoma ex-PA.11 The central
Fig. 1 Fusion genes involving HMGA2 or PLAG1 and somatic mutations targeting HRAS, PIK3CA, AKT1 and PIK3R1 in breast
adenomyoepitheliomas. a Heatmap depicting fusion gene and somatic mutations targeting HRAS Q61, PIK3CA and AKT E17 hotspot loci
and PIK3R1 mutations identiﬁed in breast adenomyoepitheliomas (AMEs; n= 13). Cases are shown in columns and genes in rows. Hotspot
mutations are annotated as per Chang et al.23 b Representative Sanger sequencing electropherograms of HRAS Q61 and PIK3CA hotspot loci in
AM16. c Representative hematoxylin and eosin micrographs of an AME harboring an HMGA2-WIF1 fusion gene (AM16), and micrographs
depicting p63 and estrogen receptor expression. Scale bars, 500 μm (upper left), 100 μm (upper right) and 50 μm (middle and lower panels). ER
estrogen receptor, FISH ﬂuorescence in situ hybridization, SNV single nucleotide variant, WT wild-type
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pathology review of all slides available from this case failed to
reveal any areas diagnostic of PA. Therefore, our ﬁndings suggest
that a subset of AMEs share not only morphologic features with
PAs, but may also resemble PAs at the genetic level. We cannot
rule out, however, that AM16 developed in the context of a PA,
which was subsequently obliterated by the outgrowth of the AME.
The FISH analysis of AM16 revealed the presence of the HMGA2-
WIF1 both in the epithelial and myoepithelial cells of the tumor
(Fig. 2b). This observation is consistent with the notion that in
AMEs, both the epithelial and myoepithelial components are
neoplastic and clonally related, even though in this AME (AM16),
the epithelial component was ER-positive, whereas the myoe-
pithelial component was ER-negative.
Our study was several limitations, such as the small size of our
cohort and the fact that we included only two HRAS-/PIK3CA-/
AKT1-wild type AMEs, given that no additional material from other
AMEs was available for transcriptomic or FISH analysis. The limited
sample size of our study precludes deﬁnitive conclusions
regarding the relationship between ER status and the presence
of the HMGA2-WIF1 fusion gene in AMEs to be drawn. Despite
these limitations, our ﬁndings demonstrate that AMEs lacking
mutations affecting HRAS, PIK3CA and AKT1 may harbor the
HMGA2-WIF1 fusion gene, previously described in salivary gland
PAs and carcinomas ex-PA,10,16 suggesting that a subset of AMEs
may be genetically related to PAs or that AMEs may originate in
the context of breast PAs.
METHODS
Cases and DNA sequencing data
This study was approved by the Institutional Review Boards (IRBs) and local
research ethics committees of the authors’ institutions. Patient consent
was obtained if required by the approved IRB protocols. In this study we
included thirteen breast AMEs, retrieved from the authors’ institutions and
previously described by Geyer et al.3 Whole-exome sequencing, MSK-
IMPACT and Sanger sequencing data, and immunohistochemical data
were retrieved from Geyer et al.3 ER status was assessed by immunohis-
tochemistry according to the current ASCO/CAP guidelines.22 Hotspot
mutations are annotated as per Chang et al.23 For power calculations, if we
posited that an HRAS-wild type AMEs would be underpinned by a recurrent
fusion gene and that this fusion gene would be present in ≥ 70% of cases
akin to recurrent fusion genes in other tumor types,9,24–26 sequencing
analysis of ﬁve samples would confer 80% power for its detection.
RNA-sequencing and the identiﬁcation of fusion transcripts
RNA-sequencing was performed on ﬁve HRAS-wild type AMEs according to
standard protocols employed at the Integrated Genomics Operation of
Memorial Sloan Kettering Cancer Center (MSKCC).27 In brief, paired-end
massively parallel RNA-sequencing (2 × 50 bp) was performed on a
HiSeq2000 (Illumina), as previously described.28 Read pairs supporting
chimeric transcripts were identiﬁed using deFuse,29 and INTEGRATE,30
followed by exclusion of candidate fusion transcripts found in a set of 287
normal breast tissues from the TCGA dataset,31 as previously described.28
The Bayesian probability of the remaining candidate fusion genes,
supported by at least two spanning reads, to constitute drivers was
annotated using OncoFuse,32 as previously described.28
Fig. 2 HMGA2-WIF1 fusion gene identiﬁed in the epithelial and myoepithelial cells of a breast adenomyoepithelioma. a Schematic
representation of the HMGA2-WIF1 fusion transcript identiﬁed in AM16, including the exons and domains involved. HMGA2 is on the (+) DNA
strand and WIF1 on the (−) DNA strand. The breakpoints of the 5’ and 3’ partner genes are represented as black vertical lines. Eight spanning
reads were found to cross the genomic breakpoint of the HMGA2-WIF1 chimeric transcript and are depicted aligned to the predicted junction
sequence. b Representative hematoxylin and eosin and FISH micrographs of the epithelial and myoepithelial components of AM16 using
HMGA2 dual-color break apart probes (red, 5′ HMGA2; green, 3′ HMGA2). aa aminoacid, AcD acidic domain, DBD DNA binding domain, E
epithelium, M myoepithelium, SpD spacer domain. Scale bar, 50 μm
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Fluorescence in situ hybridization (FISH)
All cases included in this study (n= 13) were subjected to FISH analysis for
HMGA2 and PLGA1 using dual-color break-apart probes following validated
protocols at the MSKCC Molecular Cytogenetics Core, as previously
described.33 The probe mix consisted of bacterial artiﬁcial chromosome
(BAC) clones mapping to 5′ HMGA2 (RP11-230G5, RP11-662G15; red) and 3′
HMGA2 (RP11-937C6, RP11-167E10; green), and BAC clones mapping to 5′
PLAG1 (RP11-92A9, RP11-111I18; red) and 3′ PLAG1 (RP11-144E19, RP11-
246A9; green). A minimum of 50 interphase nuclei were analyzed for HMGA2
or PLAG1 rearrangements. Cases were considered positive for rearrangement
if separation of the 5′ (red) and 3′ (green) signals (>2 signal width apart) was
identiﬁed in >15% tumor cells. FISH analyses were performed with observers
blinded to the results of the RNA-sequencing analysis.
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